JG
SPRY icon

Joel Greenblatt’s ARS Pharmaceuticals SPRY Stock Holding History

Joel Greenblatt’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,256
Closed -$476K – 1813
2025
Q2 		$476K Buy
27,256
+14,227
+109% +$205K ﹤0.01% 1334
2025
Q1 		$164K Buy
+13,029
New +$157K ﹤0.01% 1481

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Joel Greenblatt's SPRY Position: Q3 2025 in Review

Joel Greenblatt sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 27,256 shares — an estimated $476K sold.

Joel Greenblatt first reported a position in SPRY in Q1 2025 and held it in 2 quarters. The position peaked at $476K in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Joel Greenblatt reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Joel Greenblatt sold 27,256 ARS Pharmaceuticals shares in Q3 2025, an estimated $476K.
  • Joel Greenblatt first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Joel Greenblatt's ARS Pharmaceuticals position peaked at $476K in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Gotham Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.